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ABSTRACT 
 
A method for the parallel solid phase synthesis (SPS) of iodinated analogues of sanofi-aventis’ type 1 cannabinoid 
(CB1) receptor inverse agonist rimonabant (acomplia®) has been developed. The method allows the synthesis of a 
range of C3 amide/hydrazide derivatives from a resin-bound C3 ester precursor. The C-Ge linkage to the Hypogel®-
200 resin is stable to the diversification conditions but allows ipso-iododegermylative cleavage using NaI/NCS even 
for the products containing the oxidatively labile hydrazide moiety. 
 
Positron emission tomography (PET) and single photon 
emission computerized tomography (SPECT) are non-
invasive, high resolution ‘molecular’ imaging techniques 
used clinically for diagnosis and monitoring of many 
medical disorders.1 The short-lived positron or gamma-
ray emitting nuclei required for these techniques [e.g. 124I 
(t½ 4.2 d) and 123I (t½ 13.2 h), respectively] must be 
incorporated into the appropriate imaging molecules 
regioselectively and rapidly. 2  For radio-iodinated aryl 
iodides this normally entails ipso-iododestannylation of 
                                                     
1 (a) Ametamey, S. M.; Honer, M.; Schubijer, P. A. Chem. Rev. 2008, 
108, 1501, (b) Willmann, J. K.; van Bruggen, N.; Dinkelborg, L. M.; 
Gambhir, S. S. ?at. Rev. Drug Disc. 2008, 7, 591. 
2 For an excellent overview of radiolabelling see: (a) Miller, P. W.; 
Long, N. J.; Vilar, R.; Gee, A. D. Angew. Chem. Int. Ed. 2008, 47, 8998. 
For radioiodination see: (b) Finn, R. Chemistry Applied to Iodine 
Radionuclides in Handbook of Radiopharmaceuticals: Radiochemistry 
and Applications, Welch, M. J.; Redvanly C. S. (Eds), John Wiley and 
Sons, 2003, (c) Bourdoiseau, M., Int. J. Radiat. Applic. Instrument.. 
Part B. ?ucl. Med. Biol. 1986, 13, 83. 
an aryl trialkyltin precursor (e.g. ArSnMe3 or ArSnnBu3) 
by radiolabelled KI or NaI in the presence of an oxidant 
followed by HPLC purification to remove all traces of 
toxic tin residues from the product.3 
We envisaged that by employing an aryl labelling 
precursor bound to an insoluble polymer via a 
trialkylgermane linker it would be possible to effect 
analogous ipso-iododegermylative labelling thereby 
obviating the need for the radiochemist to handle tin-
containing materials and also the requirement for any post 
reaction purification.4,5 Ge-containing compounds do not 
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Hunter, D. H.; Zhu, X. J. Labelled Compd. Radiopharm. 1999, 42, 653, 
have the adverse toxicity profile of their Sn congeners6 
and the only molecules released into solution should be 
those of the labelled product. Moreover, unlike 
arylstannanes, arylgermanes are robust towards a wide 
range of conditions for chemical synthesis7 and so afford 
the possibility to make a range of derivatives of an 
advanced precursor prior to final radioiodinative release; 
a potentially valuable feature during preclinical imaging 
agent development. Herein, we describe proof-of-concept 
for this approach as exemplified by the parallel, solid 
phase synthesis (SPS) of a small array of iodinated 
analogues of the CB1 receptor inverse agonist rimonabant. 
Type 1 cannabinoid (CB1) receptors belong to the 
rhodopsin family of G protein coupled receptors (GPCRs) 
and are widely distributed in the central nervous system 
(CNS).8 Physiologically, they are implicated in regulation 
of pain, energy distribution and metabolism. Drug 
candidates acting as antagonists/inverse agonists for these 
receptors have been/are in clinical trials for treatment of 
obesity, metabolic syndrome and various addictions 
including smoking. 9  Rimonabant (1a, marketed as 
acomplia®) is a CB1 receptor inverse agonist first 
approved for treatment of obesity by the European 
Medicines Agency in 2006 and then withdrawn from the 
market in 2008 following the emergence of psychiatric 
disorders among patients. 10  Various 11C-labelled, 11  18F-
labelled, 12  and I123/124-labelled 13  derivatives (e.g. 1b 
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[123I]AM251 and 1c [123I]AM281, Fig. 1) have proved to 
be viable for PET and SPECT imaging of CNS activity 
but an optimal ligand has yet to be identified.14 
 
Figure 1 Structures of rimonabant, AM251 & AM281 
 
All reported rimonabant-derived radioiodinated ligands 
contain the labelled iodine atom in place of the chlorine 
atom in the C5 aryl ring; this substitution marginally 
reduces affinity but increases selectivity for binding at 
CB1 vs. CB2. Their synthesis involves solution phase 
Pd(0)-mediated stannylation of an arylbromide late 
intermediate (e.g. 5 → 6, Scheme 1) then ipso-
iododestannylation with a radiolabelled iodonium source 
(e.g. 6 → 1c, Scheme 1).13 
 
Scheme 1 Standard synthesis of a radio-iodinated 
rimonabant analogue (e.g. AM281) 
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Eur. J. Pharmacol. 1996, 307, 331. 
14 For reviews see: (a) Van Laere, K. Eur. J. ?ucl. Med. Mol. Imaging 
2007, 34, 1719, (b) Gifford, A. N.; Makriyannis, A.; Volkow, N. D.; 
Gatley, S. J. Chem. Phys. Lipids 2002, 12, 65. 
Experimental structure activity relationship (SAR) data, 
particularly in the context of previous attempts to develop 
effective PET ligands, show that the nature of the C3 
hydrazide moiety has a profound effect on the affinity and 
biodistribution of rimonabant analogues for the CB1 
receptor,9a, 15  making this unit an attractive target for 
variation to allow imaging agent optimization. 
Consequently, our plan was to prepare a 1,5-
diarylpyrazole bound to an insoluble polymer support by 
a Ge linker (attached at the para position of the C5 aryl 
ring) and containing an ester at C3 that could be readily 
converted via parallel SPS into an array of 
hydrazide/amide derivatives. Such a strategy would allow 
the rapid preparation of an array of potential imaging 
agents from a single functionalized polymer provided that 
the Ge-linker was stable to the C3 diversification protocol 
and ipso-iododegermylation could be achieved in the 
presence of an oxidatively labile 16  hydrazide moiety. 
Arylgermanes are uniquely stable towards basic and 
nucleophilic conditions as compared to arylstannane and 
arylsilane congeners17 so we were confident of the former 
requirement but we were cognizant that arylgermanes 
undergo SEAr reactions less rapidly than arylstannanes 
(due to their lesser β-effect)18 and so we expected careful 
optimization of the cleavage conditions would be required 
to allow rapid clean cleavage without side-reactions 
(Scheme 2).  
 
Scheme 2 Planned approach to an array of iodinated 
rimonabant analogues 1 via ipso-iododegermylation of 
functionalsed polymers prepared by parallel SPS. 
 
Our initial studies used a solution phase model system 
11 which was prepared by transmetallation of lithiated 
1,5-diarylpyrazole tert-butyl ester 4 (Scheme 1) with 
germylbromide 9 followed by LiHMDS-mediated 
amidation 19  with N-aminomorpholine. The ethoxyethyl 
                                                     
15 (a) Tobiishi, S.; Sasada, T.; Nojiri, Y.; Yamamoto, F.; Mukai, T.; 
Ishiwata, K.; Maeda, M. Chem. Pharm. Bull. 2007, 55, 1213, (b) 
Donohue, S. R.; Halldin, C.; Pike, V. W. Bioorg. Med. Chem. 2006, 14, 
3712, (c) Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S. R.; McCallion, 
D.; Pertwee, R.; Makriyannis, A. J. Med. Chem. 1999, 42, 769, (d) 
Thomas, B. F.; Francisco, M. E. Y.; Seltzman, H. H.; Thomas, J. B.; 
Fix, E. E.; Schulz, A.-K.; Gilliam, A. F.; Pertwee, R. G.; Stevenson, L. 
A. Bioorg. Med. Chem. 2005, 13, 5463. 
16 (a) Amos, R. J. I.; Corulay, B. S.; Schiesser, C. H.; Smith, J. A.; 
Yates, B. F. Chem. Commun. 2008, 1695, (b) Stieber, F.; Grether, U.; 
Waldmann, H. Angew. Chem. Int. Ed. 1999, 38, 1073. 
17  Turner, D. J.; Anemian, R.; Mackie, P. R.; Cupertino, D. C.; 
Yeates, S. G.; Turner, M. L.; Spivey, A. C. Org. Biomol. Chem. 2007, 5, 
1752. 
18 Eaborn, C.; Pande, K. C. J. Chem. Soc. 1960, 1566. 
19  cf. Gustafsson, T.; Pontén, F.; Seeberger, P. H. Chem. Comm. 
2008, 1100. 
group appended to the linker was present to mimic a PEG 
grafted polymer support. A range of conditions was 
evaluated for ipso-iododegermylation of this model 
system to give AM281 (1c, Table 1). 
 
Table 1 Synthesis of and screening ipso-
iododgermylation conditions on a solution phase germyl-
AM281 precursor 
 
entry conditionsa yield (%) 
1 NaI, chloramine T, AcOH, rt, 16 h 0c
2 I2, CCl4, rt, 16 h 0c 
3 NaI, FeCl3, rt, 16 h 0c 
4 ICl, rt, 16 h 0c 
5 NH4I, Oxone®, rt, 16 h 0c 
6 NaI, m-CPBA, rt, 16 hb 0d 
7 NaI, AcO2H, AcOH, rt, 16 hb 0d 
8 NIS, TFA (cat.), AcOH, rt, 16 h 0d 
9 I2, AcOH, rt, 16 h 15e 
10 I2, TFA, AcOH, rt, 16 hf 63e 
11 NaI, NCS,TFA, AcOH, rt, 30 minf 85 
a All reactions were carried out with 2 equiv of reagents. b slow addition 
of peracids c No reaction occurred; recovery of S.M. d Decomposition of 
S.M. e by-product 12 also isolated (see text).  f TFA-AcOH (1:3 v/v). 
Subjection of arylgermane 11 to the conditions 
reported by Gatley13d,13f for ipso-iododestannylation to 
give AM281 using NaI/chloramine-T/AcOH4a or 
I2/CCl44a,b effected no reaction; starting material was 
recovered quantitatively (entries 1 and 2). Use of 
NaI/FeCl3, 20  NH4I/Oxone® 21  and ICl4b was similarly 
ineffective (entries 3-5). By contrast, use of NaI/m-
CPBA,22 NaI/AcO2H,23 and NIS/TFA24 resulted only in 
decomposition of the starting material, even with slow 
                                                     
20 Mohanakrishnan, A.; Prakash, C.; Ramesh, N. Tetrahedron 2006, 
62, 3242. 
21 Mohan, K. V. V. K.; Narrender, N.; Kulkarni, S. J. Tetrahedron 
Lett. 2004, 45, 8015. 
22 Sha, C.-K.; Young, J.-J.; Jean, T.-S. M. J. Org. Chem. 1987, 52, 
3919. 
2323 Katsifis, A.; Mattner, F.; Zhang, Z.; Dikic, B.; Papazian, V. J. 
Labelled Cpd. Radiopharm. 2000, 43, 385. 
24  Castanet, A.-S.; Colobert, F.; Broutin, P. E. Tetrahedron Lett. 
2002, 43, 504. 
addition of the oxidants (entries 6-8). However, the use of 
I2/AcOH, as described by Moerlein for ipso-
iododegermylation of aryltrimethylgermanes,4b resulted in 
a sluggish reaction (16 h) which yielded AM281 (1a) in 
15% yield along with protonated by-product 12 in 10% 
yield (entry 9). Using TFA in place of AcOH gave an 
improved outcome: 1a (63%), 12 (10%), but the reaction 
remained slow (16 h, entry 10). Further optimization of 
these conditions led to the use of NaI/NCS in a 
TFA/AcOH solvent system which gave AM281 (1a) in 
85% yield with no by-product 12 observed, in just 30 min 
(entry 11). This protocol was considered sufficiently 
efficient to merit its deployment for our envisaged SPS 
for which we opted to employ the PEG-grafted, cross-
linked polystyrene HypoGel®-200 as the polymer support 
on account of its favourable swelling characteristics in 
hydrophilic solvents. 
HypoGel®-bound 1,5-diarylpyrazole tert-butyl ester 15 
was prepared by an analogous protocol to that used for 
the solution model 10 but employing HypoGel®-bound 
germanium bromide 14 (0.75 mmol g-1) for the 
transmetalation. Parallel amidation of functionalised 
polymer 15 with 3 × hydrazines and 2 × amines gave 
HypoGel®-bound 1,5-arylpyrazolyl hydrazides/amides 
16a-e (0.35-0.42 mmol g-1, Table 2). 
 
Table 2 Preparation of an array of HypoGel®-bound 




entry substrate time product yield (%)
1 16a 1 h AM281 (1c) 63
 
2 16b 1 h
 AM251 
(1b) 60 
3 16c 1 h 17 60 
4 16d 1 h 18 55 
5 16e 6 h 19 42
6 16b 5 min 1b 8
 
a reaction conditions: 16 (1.0 equiv), NaI (5.0 equiv), NCS (4.0 equiv), 
TFA-AcOH (1 ml, 1:3 v/v), rt 
Cleavage of the Ge linker with concomitant ipso-
iodination was accomplished by mixing functionalized 
polymers 16a-e with NaI in individual reaction cartridges, 
swelling the polymers in CH2Cl2 and then adding a 
solution of NCS in TFA/AcOH at rt. Iodinated 
rimonabant analogues 1c, 1b and 17-19 were then 
isolated in 42-63% yields (based on polymer loading 
levels) following removal of the polymer by filtration and 
then flash chromatography (entries 1-5). The reactions in 
entries 1-4 were complete within 1 h whereas that of entry 
5 (the 4-fluoroanilino amide) required 6 h to reach 
completion. Exposure of polymer 16b to the iodination 
conditions for just 5 min furnished AM251 (1b) in 8% 
yield after flash chromatography (entry 6). Analysis by 
HPLC with UV detection at 254 nm of the crude reaction 
mixture in the case of entry 2 revealed a purity of 80% 
due to contamination with succinimide (from the NCS). 
This impurity could be removed by briefly shaking the 
crude product mixture with a hydrazine functionalized Si-
propyl® scavenger resin then filtration; this gave AM251 
(1b) in a purity of 96% without recourse to 
chromatography (see Supporting Information). These 
findings augur well for adaption of our approach to radio-
iodination in a time-critical imaging context with the 
prospect of in-line purification through a scavenger 
cartridge for clinical application.25  
In conclusion, a novel protocol for the rapid parallel 
SPS of iodinated 1,5-diarylpyrazole CB1 receptor ligands 
has been developed. The method features the use of a Ge 
linker which is both robust enough to allow on-resin 
diversification by LiHMDS-mediated amidation and 
reactive enough to allow rapid and clean ipso-
iododegermylative cleavage. In particular, the method 
obviates the use of toxic and labile arylstannane 
congeners in solution as is presently widely practiced in 
this type of chemistry. We believe the method holds 
promise for application in the development of 
radioiodinated CB1 receptor ligands as candidate 
PET/SPECT imaging agents for studying a range of CNS 
disorders and could be adapted to expedite development 
of other PET imaging ligands. 
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